Targeting Angiotensinogen With N -Acetylgalactosamine–Conjugated Small Interfering RNA to Reduce Blood Pressure
Open Access
- 1 December 2023
- journal article
- review article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 43 (12) , 2256-2264
Abstract
Blood pressure management involves antihypertensive therapies blocking the renin-angiotensin system (RAS). Yet, it might be inadequate due to poor patient adherence or the so-called RAS escape phenomenon, elicited by the compensatory renin elevation upon RAS blockade. Recently, evidence points toward targeting hepatic AGT (angiotensinogen) as a novel approach to block the RAS pathway that could circumvent the RAS escape phenomenon. Removing AGT, from which all angiotensins originate, should prevent further angiotensin generation, even when renin rises. Furthermore, by making use of a trivalent N -acetylgalactosamine ligand–conjugated small interfering RNA that specifically targets the degradation of hepatocyte-produced mRNAs in a highly potent and specific manner, it may be possible in the future to manage hypertension with therapy that is administered 1 to 2× per year, thereby supporting medication adherence. This review summarizes all current findings on AGT small interfering RNA in preclinical models, making a comparison versus classical RAS blockade with either ACE (angiotensin-converting enzyme) inhibitors or AT1 (angiotensin II type 1) receptor antagonists and AGT suppression with antisense oligonucleotides. It ends with discussing the first-in-human study with AGT small interfering RNA.Keywords
This publication has 64 references indexed in Scilit:
- Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in miceAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2012
- Urinary Angiotensinogen as a Novel Biomarker of the Intrarenal Renin-Angiotensin System Status in Hypertensive PatientsHypertension, 2009
- The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?European Heart Journal, 2008
- Angiotensin Production by the HeartCirculation, 1998
- Angiotensin II Type 1 (AT1) Receptor–Mediated Accumulation of Angiotensin II in Tissues and Its Intracellular Half-life In VivoHypertension, 1997
- Prorenin, Renin, Angiotensinogen, and Angiotensin-Converting Enzyme in Normal and Failing Human HeartsCirculation, 1997
- Renin-Angiotensin System Components in the Interstitial Fluid of the Isolated Perfused Rat HeartHypertension, 1997
- Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides.Hypertension, 1994
- Cardiac angiotensinogen and its local activation in the isolated perfused beating heart.Circulation Research, 1990
- Reactive Hyperreninemia Is a Major Determinant of Plasma Angiotensin II During ACE InhibitionJournal of Cardiovascular Pharmacology, 1990